UKHIFU - High Intensity Focused Ultrasound contact us  
Text Size: Small Text Medium Text Large Text








April 17, 2012
Lancet Oncology Study
Study shows significant side effect reduction with HIFU to treat prostate cancer... more >


Sky News, April 17, 2012
Prostate Cancer Treatment 'Reduces Side Effects'
A high-powered beam of ultrasound can destroy prostate cancer without causing the serious side effects... more >


Urology Times, May 1, 2012
Data show low morbidity of HIFU in short-term trials
Technique appears safe, but evaluation of efficacy awaits longer-term data... more >

Contact Us

UKHIFU, Ltd, (“UK HIFU”) a subsidiary of USHIFU, LLC, (“US HIFU”) is the London-based European distributor of the Sonablate® 500 medical device. UK HIFU is committed to treating prostate cancer using high intensity focused ultrasound (HIFU) with the Sonablate 500, a minimally invasive outpatient procedure pioneered to control cancer and significantly improve patients’ quality of life.

The device allows physicians to precisely define treatment zones in order to destroy the entire gland or select tissue to be treated focally. Sonablate HIFU can treat large prostate up to 40 grams, without the need for a transurethral resection of the prostate (TURP), and incorporates three-dimensional imaging, monitoring of tissue changes and detection of neurovascular bundles during HIFU therapy.

UK HIFU’s vision is to become the recognized global leader in research, development and utilization of HIFU and revolutionize the delivery of minimally invasive patient care while lowering healthcare costs. Currently the Sonablate HIFU procedure is available in almost 20 hospitals throughout the UK, and in more than 30 countries worldwide.

For questions about UK HIFU please contact:
+44 (0)20 7691 3560
vicgriffin@ukhifu.com


Copyright © 2012 UKHIFU | All rights reserved